Author:
Patarroyo Manuel E.,Patarroyo Manuel A.,Alba Martha P.,Pabon Laura,Rugeles María T.,Aguilar-Jimenez Wbeimar,Florez Lizdany,Bermudez Adriana,Rout Ashok K.,Griesinger Christian,Suarez Carlos F.,Aza-Conde Jorge,Reyes César,Avendaño Catalina,Samacá Jhoan,Camargo Anny,Silva Yolanda,Forero Martha,Gonzalez Edgardo
Abstract
Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRβ1* molecules for use in humans. This was aimed at producing the first minimal subunit-based, chemically-synthesised, immunogenic molecules (COLSARSPROT) covering several HLA alleles. They were predicted to cover 48.25% of the world’s population for 6 weeks (short-term) and 33.65% for 15 weeks (long-lasting) as they induced very high immunofluorescent antibody (IFA) and ELISA titres against S, M and E parental native peptides, SARS-CoV-2 neutralising antibodies and host cell infection. The same immunological methods that led to identifying new peptides for inclusion in the COLSARSPROT mixture were used for antigenicity studies. Peptides were analysed with serum samples from patients suffering mild or severe SARS-CoV-2 infection, thereby increasing chemically-synthesised peptides’ potential coverage for the world populations up to 62.9%. These peptides’ 3D structural analysis (by 1H-NMR acquired at 600 to 900 MHz) suggested structural-functional immunological association. This first multi-protein, multi-epitope, minimal subunit-based, chemically-synthesised, highly immunogenic peptide mixture highlights such chemical synthesis methodology’s potential for rapidly obtaining very pure, highly reproducible, stable, cheap, easily-modifiable peptides for inducing immune protection against COVID-19, covering a substantial percentage of the human population.
Subject
Immunology,Immunology and Allergy
Reference88 articles.
1. COVID-19: Coronavirus Vaccine Development Updates;Zhao;Front Immunol,2020
2. Development of an Inactivated Vaccine Candidate for SARS-CoV-2;Gao;Science,2020
3. Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-in-Human Trial;Zhu;Lancet,2020
4. Immunogenicity of a DNA Vaccine Candidate for COVID-19;Smith;Nat Commun,2020
5. An mRNA Vaccine Against SARS-CoV-2 - Preliminary Report;Jackson;New Engl J Med,2020
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献